Skip to main content
Log in

Les tumeurs germinales du testicule de stade I

Stage I Testicular Germ Cell Tumors

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

Les stades I des tumeurs germinales testiculaires sont les plus fréquents, avec un taux de guérison de plus de 99 %, quels que soient l’histologie et le traitement choisi. Il est défini, après l’orchidectomie, par la normalité du scanner thoracoabdominopelvien, et la normalisation des marqueurs tumoraux dans un délai en fonction du taux et de leur demivie. Le PET-scan n’a aucune place dans le bilan d’extension. Dans les tumeurs non séminomateuses, la présence d’emboles définit un groupe à haut risque de récidive pour lequel une chimiothérapie par deux cures de BEP est conseillée. Les patients sans emboles sont préférentiellement surveillés. Le curage de stadification a une place très marginale à ce stade. Il n’existe pas de facteur de stratification pour les séminomes. La radiothérapie lomboaortique a été supplantée par la surveillance qui représente la référence, une cure unique de carboplatine AUC = 7 est l’autre option. Le respect strict des modalités de surveillance est le garant de la guérison.

Abstract

State I testicular germ cell tumors are actually the most frequent ones, with a cure rate approaching 99%, whatever the histology or the chosen treatment. After orchidectomy it is defined by a normal thoraco-abdomino-pelvic CT scan and a normalized tumor marker, which depends on the initial level and the half-life. The PET CT has no place in the treatment. In the non-seminoma germ cell tumors, the presence of lymphovascular emboli defines a group with a high relapse rate, where an adjuvant chemotherapy with 2 courses of BEP is advised. Patients without emboli are preferably watched. A staging retroperitoneal node dissection has a marginal place. Regarding seminoma, no clear stratification factor is available. Lombo-aortic radiotherapy has been replaced by surveillance as standard treatment, while one single course of carboplatin (AUC 7) is an option. The strict implementation of the follow-up guidelines is mandatory to achieve the expected cure rate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Références

  1. Albers P, Albrecht W, Algaba F, et al. (2013) Guidelines on testicular cancer. In: EAU Guidelines, edition presented at the 28th EAU Annual Congress, Milan 2013. ISBN 978-90-79754-70-0

    Google Scholar 

  2. Albers P, Siener R, Krege S, et al. (2008) Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 26: 2966–2972

    Article  CAS  PubMed  Google Scholar 

  3. Aparicio J, Germà JR, García del Muro X, et al. (2005) Riskadapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. J Clin Oncol 23: 8717–8723

    Article  PubMed  Google Scholar 

  4. Camparo P, Molinié V, Sibony M (2006) Histologie des tumeurs germinales du testicule de l’adulte. In: Camparo P, Vieillefond A, Molinié V, Sibony M (eds) Pathologie du testicule et des organes génitaux externes masculins. Elsevier, Paris, pp. 92–126

    Google Scholar 

  5. Chung P, Sridharan S, Jewett M, et al. (2013) Contemporary management of stage I and stage II seminoma. Int J rad Oncol Biol 97: 2S (#206) S 84

    Google Scholar 

  6. Chung P, Warde P (2011) Stage I seminoma: adjuvant treatment is effective but is it necessary? JNCI 103: 194–196

    Article  PubMed  Google Scholar 

  7. De Santis M, Bachner M, Lawrentschuk N, et al. (2010) In: Pilar-Laguna M, Albers P, Bokemeyer K, Richie JP (eds) Cancer of the testis. Springer-Verlag, London, pp. 75–94

  8. Dieckmann KP, Brüggeboes B, Pichlmeier U, et al. (2000) Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? Urology 55: 102–106

    Article  CAS  PubMed  Google Scholar 

  9. Donohue JP, Foster RS, Rowland RG, et al. (1990) Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 144: 287–291

    CAS  PubMed  Google Scholar 

  10. Droz JP, van Oosterom AT (1993) Treatment options in clinical stage I non-seminomatous germ cell tumours of the testis: a wager on the future? A review. Eur J Cancer 29A: 1038–1044

    Article  CAS  PubMed  Google Scholar 

  11. Durand X, Rigaud J, Avances C, et al. (2013) Recommandations 2013 du CCAFU: tumeurs germinales du testicule. Progrès Urol 23 S145–S160

    Article  Google Scholar 

  12. Fossa SD, Horwich A, Russell JM, et al. (1999) Optimal planning target volume for stage I testicular seminoma: a Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. J Clin Oncol 17: 1146

    CAS  PubMed  Google Scholar 

  13. Giwercman A, Müller J, Skakkebaek NE (1991) Carcinoma in situ of the testis: possible origin, clinical significance, and diagnostic methods. Recent Results Cancer Res 123: 21–36

    Article  CAS  PubMed  Google Scholar 

  14. Haugnes HS, Wethal T, Aass N, et al. (2010) Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: a 20-year follow-up study. J Clin Oncol 28: 4649–4657

    Article  PubMed  Google Scholar 

  15. Hilton S, Herr HW, Teitcher JB, et al. (1997) CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol 169: 521–525

    Article  CAS  PubMed  Google Scholar 

  16. Huddart RA, O’Doherty MJ, Padhani A, et al. (2007) 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22 — the NCRI Testis Tumour Clinical Study Group. J Clin Oncol 25: 3090–3095

    Article  PubMed  Google Scholar 

  17. Jones WG, Fossa SD, Mead GM, et al. (2005) Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I testicular seminoma. J Clin Oncol 23: 1200–1208

    Article  PubMed  Google Scholar 

  18. Matsuda T, Huyghe E, Thonneau P (2002) Incidence du cancer du testicule au niveau mondial. Andrologie 12: 149–155

    Article  Google Scholar 

  19. Mortensen MS, Gundgaard MG, Lauritsen J, et al. (2013) A nationwide cohort study of surveillance for stage I seminoma. J Clin Oncol 31 (suppl; abstr 4502)

  20. Oliver RT, Mead GM, Rustin GJ, et al. (2011) Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 29: 957–962

    Article  CAS  PubMed  Google Scholar 

  21. Oliver RTD (2005) Epidemiology of testis cancer. In: Vogelzang NJ, Shipley WU, Scardino PT, Debruyne FMJ (eds). Comprehensive textbook of genito-urinary oncology. 3rd ed. Lippincott Williams Wilkins, Philadelphia, pp. 547–558

    Google Scholar 

  22. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74–108

    Article  PubMed  Google Scholar 

  23. Rustin GJ, Mead GM, Stenning SP, et al. (2007) Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 — -the National Cancer Testis Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 25: 1310–1315

    Article  PubMed  Google Scholar 

  24. Stephenson AJ, Gilligan TD (2012) Neoplasm of the testis. In: Wein AJ, Kavoussi LR, Novick AC, et al. (eds) Campbell-Walsh Urology. Elsevier-Saunders, pp. 837–870

    Chapter  Google Scholar 

  25. Stephenson AJ, Sheinfeld J (2005) Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol 6: 367–377

    Article  PubMed  Google Scholar 

  26. Strader CH, Weiss NS, Daling JR, et al. (1988) Cryptorchism, orchiopexy, and the risk of testicular cancer. Am J Epidemiol 127: 1013–1018

    CAS  PubMed  Google Scholar 

  27. Tandstad T, Dahl O, Cohn-Cedermark G, et al. (2009) Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 27: 2122–2128

    Article  PubMed  Google Scholar 

  28. Travis LB, Fosså SD, Schonfeld SJ, et al. (2005) Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. JNCI 97: 1354–1365

    Article  PubMed  Google Scholar 

  29. Warde P, Specht L, Horwich A, et al. (2002) Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 20: 4448–4452

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to N. Mottet.

About this article

Cite this article

Fléchon, A., Mottet, N. Les tumeurs germinales du testicule de stade I. Oncologie 16, 154–160 (2014). https://doi.org/10.1007/s10269-014-2384-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-014-2384-4

Mots clés

Keywords

Navigation